裘氏补肾活血方联合低分子肝素对子宫动脉血流异常致复发性流产的临床疗效观察

注册号:

Registration number:

ITMCTR2200005707

最近更新日期:

Date of Last Refreshed on:

2021-07-06

注册时间:

Date of Registration:

2021-07-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

裘氏补肾活血方联合低分子肝素对子宫动脉血流异常致复发性流产的临床疗效观察

Public title:

Clinical Observation of Qiu's Bushen Huoxue Decoction Combined with Low Molecule Heparin on Recurrent Abortion Caused by Abnormal Uterine Artery Blood Flow

注册题目简写:

English Acronym:

研究课题的正式科学名称:

裘氏补肾活血方联合低分子肝素对子宫动脉血流异常致复发性流产的临床疗效观察

Scientific title:

Clinical Observation of Qiu's Bushen Huoxue Decoction Combined with Low Molecule Heparin on Recurrent Abortion Caused by Abnormal Uterine Artery Blood Flow

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100048346 ; ChiMCTR2200005707

申请注册联系人:

张丽

研究负责人:

张丽

Applicant:

Zhang Li

Study leader:

Zhang Li

申请注册联系人电话:

Applicant telephone:

+86 15888875872

研究负责人电话:

Study leader's telephone:

+86 15888875872

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qjsy1991@126.com

研究负责人电子邮件:

Study leader's E-mail:

qjsy1991@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市上城区邮电路54号

研究负责人通讯地址:

浙江省杭州市上城区邮电路54号

Applicant address:

54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang

Study leader's address:

54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

310000

研究负责人邮政编码:

Study leader's postcode:

310000

申请人所在单位:

浙江省中医院

Applicant's institution:

Zhejiang Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江省中医院

Primary sponsor:

Zhejiang Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

浙江省杭州市上城区邮电路54号

Primary sponsor's address:

54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江省中医院

具体地址:

上城区邮电路54号

Institution
hospital:

Zhejiang Hospital of Traditional Chinese Medicine

Address:

54 Youdian Road, Shangcheng District

经费或物资来源:

浙江省中医药管理局

Source(s) of funding:

Zhejiang Provincial Administration of Traditional Chinese Medicine

研究疾病:

复发性流产

研究疾病代码:

Target disease:

recurrent spontaneous abortion, RSA

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本项目充分发挥中医药治疗子宫动脉血流异常致复发性流产的特色优势。通过中医药干预,提高结该疾病的治疗有效率,为优化和推广中西医综合治疗方案提供证据。

Objectives of Study:

This project gives full play to the characteristic advantages of traditional Chinese medicine in treating recurrent abortion caused by abnormal uterine artery blood flow.Through medical intervention, the project will improve the effective rate of the treatment of this disease, and provide evidence for the optimization and promotion of the comprehensive treatment plan of traditional Chinese and western medicine.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合《实用妇产科学》制定的复发性流产西医诊断标准; 2.存在子宫动脉血流参数异常:一侧或双侧子宫动脉血流阻力指数(RI)>=0.8,或双侧子宫动脉收缩期峰值流速/舒张末期流速(S/D)之和>=12。

Inclusion criteria

1.In line with the western medicine diagnosis of recurrent abortion standards developed by the "practical obstetrics and gynecology"; 2.Abnormal uterine artery flow parameters: one or both uterine artery flow resistance index (RI) >=0.8, or the sum of peak systolic flow rate/end diastolic flow rate (S/D) of uterine arteries is >=12.

排除标准:

1.存在其他致复发性流产疾病如染色体异常、生殖系统解剖畸形、遗传性疾病、内分泌功能异常、自身免疫性抗体阳性等; 2.严重心肝肾器质性疾病; 3.合并肿瘤或血液系统疾病者; 4.有低分子肝素禁忌症,如肝肾功能不全、出血等; 5.依从性差,难以配合者。

Exclusion criteria:

1.There are other causes of recurrent abortion diseases such as chromosomal abnormalities, anatomical malformation of the reproductive system, genetic diseases, abnormal endocrine function, autoimmune antibody positive, etc.; 2.There are serious organic diseases of heart, liver and kidney; 3.Complicated with tumor or blood system disease; 4.There are contraindications to low molecular weight heparin, such as liver and kidney insufficiency, bleeding, etc.; 5.Poor compliance, difficult to cooperate.

研究实施时间:

Study execute time:

From 2022-01-01

To      2024-12-31

征募观察对象时间:

Recruiting time:

From 2022-01-01

To      2023-12-31

干预措施:

Interventions:

组别:

观察组

样本量:

120

Group:

Observation group

Sample size:

干预措施:

裘氏补肾活血方+低分子肝素

干预措施代码:

Intervention:

Qiu's recipe for tonifying kidney and promoting blood circulation+ low molecular heparin

Intervention code:

组别:

对照组

样本量:

120

Group:

Control group

Sample size:

干预措施:

低分子肝素

干预措施代码:

Intervention:

Low molecular heparin

Intervention code:

样本总量 Total sample size : 240

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省中医院

单位级别:

三级甲等

Institution/hospital:

Zhejiang Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子宫动脉血流参数

指标类型:

主要指标

Outcome:

Uterine artery blood flow parameters

Type:

Primary indicator

测量时间点:

经前一周

测量方法:

阴道B超检查

Measure time point of outcome:

One week before menstruation

Measure method:

Vaginal ultrasound examination

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

Traditional Chinese medicine syndrome integral

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表法分为两组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Two groups were divided by random number table method.

盲法:

不采用盲法

Blinding:

No blind method is used

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网络平台。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Network platform.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床试验公共管理平台。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Clinical Trial Public Management platform.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统